Cat. #161946


Cat. #: 161946

Organism: Human

Tissue: Epithelial

Disease: Cancer

Model: Knockdown


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: Marta Martins

Institute: Instituto de Medicina Molecular João Lobo Antunes

Primary Citation: Martins, et al. 2022. Clin Cancer Res. 28(6):1203-1216. PMID: 34980600

Tool Details
Target Details

Tool Details


  • Name: CACO-2-shPLCG1
  • Parental cell: CACO-2
  • Organism: Human
  • Gender: Male
  • Tissue: Epithelial
  • Disease: Cancer
  • Growth properties: A subcultivation ratio of 1:4 to 1:6 is recommended, 1 to 2 times per week.
  • Model: Knockdown
  • Crispr: No
  • Description: CACO-2 cells were infected with PLCG1 shRNA lentiviral particles (Santa Cruz Biotechnology) for knocking down the gene. Selection of stable clones started 2 days after infection with 10 ?g/mL Puromycin.
  • Biosafety level: 1
  • Recommended controls: shRNA scrambled control

Target Details

  • Target: PLCG1
  • Target background: Phospholipase C gamma 1 is a ubiquitously expressed enzyme that catalyses the formation of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate. This reaction plays an important role in the intracellular transduction of receptor- and non-receptor- mediated tyrosine kinase activators, which has major implications in several cellular processes such as proliferation, migration, and angiogenesis. More recently, PLC?1 was shown involved in anti-EGFR therapy re...


  • Format: Frozen
  • Growth medium: DMEM with 10% FBS, 5% CO2
  • Shipping conditions: Dry Ice
  • Storage conditions: Liquid Nitrogen


  • Martins, et al. 2022. Clin Cancer Res. 28(6):1203-1216. PMID: 34980600